nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—CYP3A4—Temozolomide—melanoma	0.121	0.576	CbGbCtD
Pimecrolimus—CYP3A4—Vemurafenib—melanoma	0.0662	0.316	CbGbCtD
Pimecrolimus—MTOR—leg—melanoma	0.0251	0.177	CbGeAlD
Pimecrolimus—CYP3A4—Docetaxel—melanoma	0.0227	0.108	CbGbCtD
Pimecrolimus—MTOR—hindlimb—melanoma	0.0224	0.158	CbGeAlD
Pimecrolimus—MTOR—appendage—melanoma	0.0192	0.135	CbGeAlD
Pimecrolimus—Squamous cell carcinoma—Vemurafenib—melanoma	0.0148	0.0629	CcSEcCtD
Pimecrolimus—Basal cell carcinoma—Vemurafenib—melanoma	0.0143	0.0606	CcSEcCtD
Pimecrolimus—Malignant melanoma—Vemurafenib—melanoma	0.0129	0.0547	CcSEcCtD
Pimecrolimus—MTOR—blood vessel—melanoma	0.0107	0.0754	CbGeAlD
Pimecrolimus—Skin papilloma—Vemurafenib—melanoma	0.0103	0.0438	CcSEcCtD
Pimecrolimus—Condition aggravated—Temozolomide—melanoma	0.0094	0.04	CcSEcCtD
Pimecrolimus—MTOR—neck—melanoma	0.00765	0.0539	CbGeAlD
Pimecrolimus—FKBP1A—neck—melanoma	0.00688	0.0485	CbGeAlD
Pimecrolimus—Sirolimus—FGF2—melanoma	0.00571	0.63	CrCbGaD
Pimecrolimus—MTOR—eye—melanoma	0.00569	0.0401	CbGeAlD
Pimecrolimus—MTOR—retina—melanoma	0.00564	0.0398	CbGeAlD
Pimecrolimus—Folliculitis—Vemurafenib—melanoma	0.00535	0.0227	CcSEcCtD
Pimecrolimus—FKBP1A—eye—melanoma	0.00512	0.0361	CbGeAlD
Pimecrolimus—FKBP1A—retina—melanoma	0.00507	0.0358	CbGeAlD
Pimecrolimus—MTOR—skin of body—melanoma	0.00495	0.0349	CbGeAlD
Pimecrolimus—MTOR—mammalian vulva—melanoma	0.00451	0.0318	CbGeAlD
Pimecrolimus—FKBP1A—skin of body—melanoma	0.00445	0.0314	CbGeAlD
Pimecrolimus—FKBP1A—mammalian vulva—melanoma	0.00406	0.0286	CbGeAlD
Pimecrolimus—Neoplasm malignant—Vemurafenib—melanoma	0.00393	0.0167	CcSEcCtD
Pimecrolimus—Skin hyperpigmentation—Bleomycin—melanoma	0.00342	0.0145	CcSEcCtD
Pimecrolimus—MTOR—head—melanoma	0.00323	0.0228	CbGeAlD
Pimecrolimus—Folliculitis—Dactinomycin—melanoma	0.00302	0.0128	CcSEcCtD
Pimecrolimus—Skin hyperpigmentation—Carmustine—melanoma	0.00299	0.0127	CcSEcCtD
Pimecrolimus—FKBP1A—head—melanoma	0.0029	0.0205	CbGeAlD
Pimecrolimus—MTOR—lymph node—melanoma	0.00226	0.0159	CbGeAlD
Pimecrolimus—Otitis media—Temozolomide—melanoma	0.00221	0.00938	CcSEcCtD
Pimecrolimus—FKBP1A—lymph node—melanoma	0.00203	0.0143	CbGeAlD
Pimecrolimus—Wheezing—Bleomycin—melanoma	0.00198	0.0084	CcSEcCtD
Pimecrolimus—Skin exfoliation—Bleomycin—melanoma	0.00194	0.00826	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Vemurafenib—melanoma	0.00192	0.00818	CcSEcCtD
Pimecrolimus—Skin hyperpigmentation—Docetaxel—melanoma	0.00192	0.00816	CcSEcCtD
Pimecrolimus—Viral infection—Temozolomide—melanoma	0.0019	0.00808	CcSEcCtD
Pimecrolimus—Infestation NOS—Vemurafenib—melanoma	0.00188	0.00799	CcSEcCtD
Pimecrolimus—Infestation—Vemurafenib—melanoma	0.00188	0.00799	CcSEcCtD
Pimecrolimus—Herpes simplex—Temozolomide—melanoma	0.00186	0.00792	CcSEcCtD
Pimecrolimus—Skin exfoliation—Carmustine—melanoma	0.0017	0.00721	CcSEcCtD
Pimecrolimus—Influenza like illness—Temozolomide—melanoma	0.00167	0.00709	CcSEcCtD
Pimecrolimus—Skin exfoliation—Temozolomide—melanoma	0.00164	0.00697	CcSEcCtD
Pimecrolimus—Throat sore—Docetaxel—melanoma	0.00158	0.00673	CcSEcCtD
Pimecrolimus—Eye disorder—Vemurafenib—melanoma	0.00158	0.0067	CcSEcCtD
Pimecrolimus—Oropharyngeal discomfort—Docetaxel—melanoma	0.00157	0.00667	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Vemurafenib—melanoma	0.00152	0.00646	CcSEcCtD
Pimecrolimus—Erythema—Vemurafenib—melanoma	0.00147	0.00624	CcSEcCtD
Pimecrolimus—Malnutrition—Vemurafenib—melanoma	0.00147	0.00624	CcSEcCtD
Pimecrolimus—Otitis media—Docetaxel—melanoma	0.00147	0.00624	CcSEcCtD
Pimecrolimus—Swelling—Carmustine—melanoma	0.00146	0.00622	CcSEcCtD
Pimecrolimus—Ear pain—Temozolomide—melanoma	0.00146	0.00621	CcSEcCtD
Pimecrolimus—Back pain—Vemurafenib—melanoma	0.00142	0.00604	CcSEcCtD
Pimecrolimus—Rhinorrhoea—Docetaxel—melanoma	0.00141	0.00599	CcSEcCtD
Pimecrolimus—Gastroenteritis—Temozolomide—melanoma	0.00141	0.00598	CcSEcCtD
Pimecrolimus—Nasal congestion—Temozolomide—melanoma	0.00137	0.00582	CcSEcCtD
Pimecrolimus—Eye irritation—Docetaxel—melanoma	0.00134	0.00568	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Temozolomide—melanoma	0.00132	0.00562	CcSEcCtD
Pimecrolimus—Cough—Vemurafenib—melanoma	0.00128	0.00545	CcSEcCtD
Pimecrolimus—Bone disorder—Docetaxel—melanoma	0.00126	0.00537	CcSEcCtD
Pimecrolimus—Oropharyngeal pain—Docetaxel—melanoma	0.00126	0.00534	CcSEcCtD
Pimecrolimus—Arthralgia—Vemurafenib—melanoma	0.00125	0.00532	CcSEcCtD
Pimecrolimus—Face oedema—Carmustine—melanoma	0.00125	0.00529	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00124	0.00528	CcSEcCtD
Pimecrolimus—Face oedema—Temozolomide—melanoma	0.0012	0.00512	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Vemurafenib—melanoma	0.0012	0.0051	CcSEcCtD
Pimecrolimus—Infection—Vemurafenib—melanoma	0.00119	0.00506	CcSEcCtD
Pimecrolimus—Nervous system disorder—Vemurafenib—melanoma	0.00118	0.005	CcSEcCtD
Pimecrolimus—Skin disorder—Vemurafenib—melanoma	0.00116	0.00495	CcSEcCtD
Pimecrolimus—Pneumonia—Bleomycin—melanoma	0.00115	0.00487	CcSEcCtD
Pimecrolimus—Breast disorder—Temozolomide—melanoma	0.00113	0.00479	CcSEcCtD
Pimecrolimus—Influenza like illness—Docetaxel—melanoma	0.00111	0.00471	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00109	0.00464	CcSEcCtD
Pimecrolimus—Skin exfoliation—Docetaxel—melanoma	0.00109	0.00463	CcSEcCtD
Pimecrolimus—Pneumonia—Dactinomycin—melanoma	0.00107	0.00454	CcSEcCtD
Pimecrolimus—Bronchitis—Temozolomide—melanoma	0.00104	0.0044	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Vemurafenib—melanoma	0.00103	0.0044	CcSEcCtD
Pimecrolimus—Constipation—Vemurafenib—melanoma	0.00103	0.00436	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Temozolomide—melanoma	0.001	0.00426	CcSEcCtD
Pimecrolimus—Pneumonia—Carmustine—melanoma	0.001	0.00425	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Temozolomide—melanoma	0.000983	0.00418	CcSEcCtD
Pimecrolimus—Pneumonia—Temozolomide—melanoma	0.000966	0.00411	CcSEcCtD
Pimecrolimus—Infestation NOS—Temozolomide—melanoma	0.000961	0.00408	CcSEcCtD
Pimecrolimus—Infestation—Temozolomide—melanoma	0.000961	0.00408	CcSEcCtD
Pimecrolimus—Flushing—Bleomycin—melanoma	0.000949	0.00403	CcSEcCtD
Pimecrolimus—Body temperature increased—Vemurafenib—melanoma	0.000948	0.00403	CcSEcCtD
Pimecrolimus—Pharyngitis—Dactinomycin—melanoma	0.000946	0.00402	CcSEcCtD
Pimecrolimus—Swelling—Docetaxel—melanoma	0.00094	0.00399	CcSEcCtD
Pimecrolimus—Temsirolimus—ABCB1—melanoma	0.000909	0.1	CrCbGaD
Pimecrolimus—Sinusitis—Temozolomide—melanoma	0.000901	0.00383	CcSEcCtD
Pimecrolimus—Erythema—Bleomycin—melanoma	0.00089	0.00378	CcSEcCtD
Pimecrolimus—Flushing—Dactinomycin—melanoma	0.000885	0.00376	CcSEcCtD
Pimecrolimus—Hypersensitivity—Vemurafenib—melanoma	0.000883	0.00375	CcSEcCtD
Pimecrolimus—Pharyngitis—Temozolomide—melanoma	0.000856	0.00364	CcSEcCtD
Pimecrolimus—Pruritus—Vemurafenib—melanoma	0.000848	0.00361	CcSEcCtD
Pimecrolimus—Tacrolimus—ALB—melanoma	0.000838	0.0926	CrCbGaD
Pimecrolimus—Eye disorder—Carmustine—melanoma	0.000834	0.00354	CcSEcCtD
Pimecrolimus—Erythema—Dactinomycin—melanoma	0.00083	0.00353	CcSEcCtD
Pimecrolimus—Flushing—Carmustine—melanoma	0.000828	0.00352	CcSEcCtD
Pimecrolimus—Diarrhoea—Vemurafenib—melanoma	0.00082	0.00349	CcSEcCtD
Pimecrolimus—Eye disorder—Temozolomide—melanoma	0.000806	0.00343	CcSEcCtD
Pimecrolimus—Flushing—Temozolomide—melanoma	0.0008	0.0034	CcSEcCtD
Pimecrolimus—Tacrolimus—ABCB1—melanoma	0.0008	0.0883	CrCbGaD
Pimecrolimus—Sirolimus—ABCB1—melanoma	0.0008	0.0883	CrCbGaD
Pimecrolimus—Immune system disorder—Temozolomide—melanoma	0.000779	0.00331	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Temozolomide—melanoma	0.000777	0.0033	CcSEcCtD
Pimecrolimus—Malnutrition—Carmustine—melanoma	0.000777	0.0033	CcSEcCtD
Pimecrolimus—Erythema—Carmustine—melanoma	0.000777	0.0033	CcSEcCtD
Pimecrolimus—Cough—Bleomycin—melanoma	0.000777	0.0033	CcSEcCtD
Pimecrolimus—Vomiting—Vemurafenib—melanoma	0.000762	0.00324	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Docetaxel—melanoma	0.000757	0.00322	CcSEcCtD
Pimecrolimus—Rash—Vemurafenib—melanoma	0.000756	0.00321	CcSEcCtD
Pimecrolimus—Dermatitis—Vemurafenib—melanoma	0.000755	0.00321	CcSEcCtD
Pimecrolimus—Back pain—Carmustine—melanoma	0.000751	0.00319	CcSEcCtD
Pimecrolimus—Headache—Vemurafenib—melanoma	0.000751	0.00319	CcSEcCtD
Pimecrolimus—Erythema—Temozolomide—melanoma	0.000751	0.00319	CcSEcCtD
Pimecrolimus—Malnutrition—Temozolomide—melanoma	0.000751	0.00319	CcSEcCtD
Pimecrolimus—Breast disorder—Docetaxel—melanoma	0.000749	0.00318	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Docetaxel—melanoma	0.000741	0.00315	CcSEcCtD
Pimecrolimus—Oedema—Bleomycin—melanoma	0.000726	0.00309	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Bleomycin—melanoma	0.000726	0.00309	CcSEcCtD
Pimecrolimus—Back pain—Temozolomide—melanoma	0.000726	0.00309	CcSEcCtD
Pimecrolimus—Infection—Bleomycin—melanoma	0.000721	0.00307	CcSEcCtD
Pimecrolimus—Nausea—Vemurafenib—melanoma	0.000712	0.00303	CcSEcCtD
Pimecrolimus—Angioedema—Temozolomide—melanoma	0.000686	0.00292	CcSEcCtD
Pimecrolimus—Oedema—Dactinomycin—melanoma	0.000677	0.00288	CcSEcCtD
Pimecrolimus—Infection—Dactinomycin—melanoma	0.000673	0.00286	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Bleomycin—melanoma	0.000662	0.00281	CcSEcCtD
Pimecrolimus—Cough—Temozolomide—melanoma	0.000655	0.00278	CcSEcCtD
Pimecrolimus—Paraesthesia—Bleomycin—melanoma	0.000652	0.00277	CcSEcCtD
Pimecrolimus—Dyspnoea—Bleomycin—melanoma	0.000647	0.00275	CcSEcCtD
Pimecrolimus—Pneumonia—Docetaxel—melanoma	0.000642	0.00273	CcSEcCtD
Pimecrolimus—Arthralgia—Temozolomide—melanoma	0.000639	0.00272	CcSEcCtD
Pimecrolimus—Infestation NOS—Docetaxel—melanoma	0.000639	0.00272	CcSEcCtD
Pimecrolimus—Infestation—Docetaxel—melanoma	0.000639	0.00272	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000635	0.0027	CcSEcCtD
Pimecrolimus—Oedema—Carmustine—melanoma	0.000634	0.00269	CcSEcCtD
Pimecrolimus—Infection—Carmustine—melanoma	0.00063	0.00268	CcSEcCtD
Pimecrolimus—Pain—Bleomycin—melanoma	0.000621	0.00264	CcSEcCtD
Pimecrolimus—Conjunctivitis—Docetaxel—melanoma	0.000621	0.00264	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000617	0.00262	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Temozolomide—melanoma	0.000613	0.0026	CcSEcCtD
Pimecrolimus—Oedema—Temozolomide—melanoma	0.000613	0.0026	CcSEcCtD
Pimecrolimus—Infection—Temozolomide—melanoma	0.000609	0.00259	CcSEcCtD
Pimecrolimus—Epistaxis—Docetaxel—melanoma	0.000602	0.00256	CcSEcCtD
Pimecrolimus—Nervous system disorder—Temozolomide—melanoma	0.000601	0.00255	CcSEcCtD
Pimecrolimus—Skin disorder—Temozolomide—melanoma	0.000595	0.00253	CcSEcCtD
Pimecrolimus—Pain—Dactinomycin—melanoma	0.000579	0.00246	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Carmustine—melanoma	0.000578	0.00246	CcSEcCtD
Pimecrolimus—Urticaria—Bleomycin—melanoma	0.000577	0.00245	CcSEcCtD
Pimecrolimus—Rhinitis—Docetaxel—melanoma	0.000575	0.00244	CcSEcCtD
Pimecrolimus—Body temperature increased—Bleomycin—melanoma	0.000574	0.00244	CcSEcCtD
Pimecrolimus—Paraesthesia—Carmustine—melanoma	0.000569	0.00242	CcSEcCtD
Pimecrolimus—Pharyngitis—Docetaxel—melanoma	0.000569	0.00242	CcSEcCtD
Pimecrolimus—Dyspnoea—Carmustine—melanoma	0.000565	0.0024	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Temozolomide—melanoma	0.000558	0.00237	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Dactinomycin—melanoma	0.000554	0.00235	CcSEcCtD
Pimecrolimus—Paraesthesia—Temozolomide—melanoma	0.00055	0.00234	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Carmustine—melanoma	0.000547	0.00233	CcSEcCtD
Pimecrolimus—Dyspnoea—Temozolomide—melanoma	0.000546	0.00232	CcSEcCtD
Pimecrolimus—Pain—Carmustine—melanoma	0.000542	0.0023	CcSEcCtD
Pimecrolimus—Constipation—Carmustine—melanoma	0.000542	0.0023	CcSEcCtD
Pimecrolimus—Eye disorder—Docetaxel—melanoma	0.000536	0.00228	CcSEcCtD
Pimecrolimus—Abdominal pain—Dactinomycin—melanoma	0.000535	0.00228	CcSEcCtD
Pimecrolimus—Body temperature increased—Dactinomycin—melanoma	0.000535	0.00228	CcSEcCtD
Pimecrolimus—Hypersensitivity—Bleomycin—melanoma	0.000535	0.00227	CcSEcCtD
Pimecrolimus—Flushing—Docetaxel—melanoma	0.000532	0.00226	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Temozolomide—melanoma	0.000529	0.00225	CcSEcCtD
Pimecrolimus—Pain—Temozolomide—melanoma	0.000524	0.00223	CcSEcCtD
Pimecrolimus—Constipation—Temozolomide—melanoma	0.000524	0.00223	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Carmustine—melanoma	0.000518	0.0022	CcSEcCtD
Pimecrolimus—Immune system disorder—Docetaxel—melanoma	0.000518	0.0022	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Docetaxel—melanoma	0.000517	0.0022	CcSEcCtD
Pimecrolimus—Pruritus—Bleomycin—melanoma	0.000514	0.00218	CcSEcCtD
Pimecrolimus—Body temperature increased—Carmustine—melanoma	0.000501	0.00213	CcSEcCtD
Pimecrolimus—Abdominal pain—Carmustine—melanoma	0.000501	0.00213	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Temozolomide—melanoma	0.000501	0.00213	CcSEcCtD
Pimecrolimus—Malnutrition—Docetaxel—melanoma	0.000499	0.00212	CcSEcCtD
Pimecrolimus—Erythema—Docetaxel—melanoma	0.000499	0.00212	CcSEcCtD
Pimecrolimus—Hypersensitivity—Dactinomycin—melanoma	0.000499	0.00212	CcSEcCtD
Pimecrolimus—Urticaria—Temozolomide—melanoma	0.000487	0.00207	CcSEcCtD
Pimecrolimus—Body temperature increased—Temozolomide—melanoma	0.000484	0.00206	CcSEcCtD
Pimecrolimus—Abdominal pain—Temozolomide—melanoma	0.000484	0.00206	CcSEcCtD
Pimecrolimus—Back pain—Docetaxel—melanoma	0.000483	0.00205	CcSEcCtD
Pimecrolimus—Hypersensitivity—Carmustine—melanoma	0.000467	0.00199	CcSEcCtD
Pimecrolimus—Diarrhoea—Dactinomycin—melanoma	0.000463	0.00197	CcSEcCtD
Pimecrolimus—Vomiting—Bleomycin—melanoma	0.000462	0.00196	CcSEcCtD
Pimecrolimus—Rash—Bleomycin—melanoma	0.000458	0.00195	CcSEcCtD
Pimecrolimus—Dermatitis—Bleomycin—melanoma	0.000457	0.00194	CcSEcCtD
Pimecrolimus—Hypersensitivity—Temozolomide—melanoma	0.000451	0.00192	CcSEcCtD
Pimecrolimus—Cough—Docetaxel—melanoma	0.000436	0.00185	CcSEcCtD
Pimecrolimus—Diarrhoea—Carmustine—melanoma	0.000434	0.00184	CcSEcCtD
Pimecrolimus—Pruritus—Temozolomide—melanoma	0.000433	0.00184	CcSEcCtD
Pimecrolimus—Nausea—Bleomycin—melanoma	0.000431	0.00183	CcSEcCtD
Pimecrolimus—Vomiting—Dactinomycin—melanoma	0.000431	0.00183	CcSEcCtD
Pimecrolimus—Rash—Dactinomycin—melanoma	0.000427	0.00182	CcSEcCtD
Pimecrolimus—Arthralgia—Docetaxel—melanoma	0.000425	0.00181	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000422	0.00179	CcSEcCtD
Pimecrolimus—Diarrhoea—Temozolomide—melanoma	0.000419	0.00178	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Docetaxel—melanoma	0.000407	0.00173	CcSEcCtD
Pimecrolimus—Oedema—Docetaxel—melanoma	0.000407	0.00173	CcSEcCtD
Pimecrolimus—Infection—Docetaxel—melanoma	0.000405	0.00172	CcSEcCtD
Pimecrolimus—Vomiting—Carmustine—melanoma	0.000403	0.00171	CcSEcCtD
Pimecrolimus—Nausea—Dactinomycin—melanoma	0.000402	0.00171	CcSEcCtD
Pimecrolimus—Rash—Carmustine—melanoma	0.0004	0.0017	CcSEcCtD
Pimecrolimus—Nervous system disorder—Docetaxel—melanoma	0.0004	0.0017	CcSEcCtD
Pimecrolimus—Dermatitis—Carmustine—melanoma	0.000399	0.0017	CcSEcCtD
Pimecrolimus—Headache—Carmustine—melanoma	0.000397	0.00169	CcSEcCtD
Pimecrolimus—Skin disorder—Docetaxel—melanoma	0.000396	0.00168	CcSEcCtD
Pimecrolimus—Vomiting—Temozolomide—melanoma	0.00039	0.00166	CcSEcCtD
Pimecrolimus—Rash—Temozolomide—melanoma	0.000386	0.00164	CcSEcCtD
Pimecrolimus—Dermatitis—Temozolomide—melanoma	0.000386	0.00164	CcSEcCtD
Pimecrolimus—Headache—Temozolomide—melanoma	0.000384	0.00163	CcSEcCtD
Pimecrolimus—Nausea—Carmustine—melanoma	0.000377	0.0016	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Docetaxel—melanoma	0.000371	0.00158	CcSEcCtD
Pimecrolimus—Paraesthesia—Docetaxel—melanoma	0.000366	0.00156	CcSEcCtD
Pimecrolimus—Nausea—Temozolomide—melanoma	0.000364	0.00155	CcSEcCtD
Pimecrolimus—Dyspnoea—Docetaxel—melanoma	0.000363	0.00154	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Docetaxel—melanoma	0.000352	0.0015	CcSEcCtD
Pimecrolimus—Pain—Docetaxel—melanoma	0.000348	0.00148	CcSEcCtD
Pimecrolimus—Constipation—Docetaxel—melanoma	0.000348	0.00148	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Docetaxel—melanoma	0.000333	0.00142	CcSEcCtD
Pimecrolimus—Abdominal pain—Docetaxel—melanoma	0.000322	0.00137	CcSEcCtD
Pimecrolimus—Body temperature increased—Docetaxel—melanoma	0.000322	0.00137	CcSEcCtD
Pimecrolimus—Hypersensitivity—Docetaxel—melanoma	0.0003	0.00128	CcSEcCtD
Pimecrolimus—Pruritus—Docetaxel—melanoma	0.000288	0.00123	CcSEcCtD
Pimecrolimus—Diarrhoea—Docetaxel—melanoma	0.000279	0.00119	CcSEcCtD
Pimecrolimus—Vomiting—Docetaxel—melanoma	0.000259	0.0011	CcSEcCtD
Pimecrolimus—Rash—Docetaxel—melanoma	0.000257	0.00109	CcSEcCtD
Pimecrolimus—Dermatitis—Docetaxel—melanoma	0.000257	0.00109	CcSEcCtD
Pimecrolimus—Headache—Docetaxel—melanoma	0.000255	0.00108	CcSEcCtD
Pimecrolimus—Nausea—Docetaxel—melanoma	0.000242	0.00103	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—GNA11—melanoma	4.04e-05	0.0001	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FLT1—melanoma	4.02e-05	9.95e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FN1—melanoma	3.97e-05	9.83e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PDGFRA—melanoma	3.94e-05	9.74e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-A—melanoma	3.92e-05	9.71e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CDKN1B—melanoma	3.92e-05	9.7e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RAC1—melanoma	3.91e-05	9.68e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CDKN1B—melanoma	3.9e-05	9.66e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PRKCA—melanoma	3.9e-05	9.64e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOTCH1—melanoma	3.89e-05	9.62e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ERCC2—melanoma	3.86e-05	9.56e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CTNNB1—melanoma	3.85e-05	9.54e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MAP2K2—melanoma	3.81e-05	9.43e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CD80—melanoma	3.81e-05	9.42e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KIT—melanoma	3.8e-05	9.4e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CG—melanoma	3.8e-05	9.4e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—APC—melanoma	3.8e-05	9.4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FOXO4—melanoma	3.8e-05	9.4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HDAC2—melanoma	3.8e-05	9.4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCR4—melanoma	3.8e-05	9.4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—AKT1—melanoma	3.8e-05	9.4e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HS3ST5—melanoma	3.78e-05	9.37e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CDKN1A—melanoma	3.77e-05	9.32e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PTEN—melanoma	3.76e-05	9.3e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGF—melanoma	3.76e-05	9.29e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GNAQ—melanoma	3.75e-05	9.29e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NFKB1—melanoma	3.74e-05	9.25e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CTNNB1—melanoma	3.69e-05	9.12e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TERT—melanoma	3.62e-05	8.96e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HLA-A—melanoma	3.62e-05	8.96e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CDKN1A—melanoma	3.62e-05	8.95e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RAC1—melanoma	3.61e-05	8.94e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PTEN—melanoma	3.61e-05	8.93e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CDKN1A—melanoma	3.6e-05	8.91e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTEN—melanoma	3.59e-05	8.89e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—NFKB1—melanoma	3.59e-05	8.89e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TLR4—melanoma	3.59e-05	8.88e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-DRB1—melanoma	3.58e-05	8.87e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—BRAF—melanoma	3.57e-05	8.84e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SYK—melanoma	3.53e-05	8.74e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IGF1—melanoma	3.48e-05	8.61e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NGFR—melanoma	3.47e-05	8.58e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT3—melanoma	3.47e-05	8.58e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ITGAV—melanoma	3.47e-05	8.58e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HIF1A—melanoma	3.46e-05	8.57e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ICAM1—melanoma	3.44e-05	8.51e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAP2K1—melanoma	3.36e-05	8.32e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NRAS—melanoma	3.35e-05	8.3e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CD—melanoma	3.34e-05	8.27e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD80—melanoma	3.31e-05	8.19e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KIT—melanoma	3.31e-05	8.18e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGF—melanoma	3.27e-05	8.09e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—NRAS—melanoma	3.22e-05	7.97e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—STAT3—melanoma	3.21e-05	7.95e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—MAPK3—melanoma	3.21e-05	7.95e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SOCS1—melanoma	3.21e-05	7.94e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NRAS—melanoma	3.21e-05	7.93e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—S100B—melanoma	3.2e-05	7.92e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGF2—melanoma	3.2e-05	7.91e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS2—melanoma	3.15e-05	7.8e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOTCH1—melanoma	3.12e-05	7.72e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CASP8—melanoma	3.08e-05	7.62e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MAPK3—melanoma	3.07e-05	7.6e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ERBB4—melanoma	3.06e-05	7.58e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD80—melanoma	3.06e-05	7.57e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—MAPK1—melanoma	3.05e-05	7.56e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EGFR—melanoma	3.05e-05	7.56e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APC—melanoma	3.05e-05	7.55e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KIT—melanoma	3.05e-05	7.55e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDH1—melanoma	3.04e-05	7.53e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN2B—melanoma	3.03e-05	7.51e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGF—melanoma	3.02e-05	7.46e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MDM2—melanoma	2.99e-05	7.41e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MYC—melanoma	2.99e-05	7.39e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ERBB2—melanoma	2.95e-05	7.3e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CD86—melanoma	2.93e-05	7.26e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—EGFR—melanoma	2.93e-05	7.26e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAP2K1—melanoma	2.92e-05	7.24e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MAPK1—melanoma	2.92e-05	7.23e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EGFR—melanoma	2.92e-05	7.23e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EDN1—melanoma	2.91e-05	7.21e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CB—melanoma	2.91e-05	7.21e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CD—melanoma	2.91e-05	7.19e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—KRAS—melanoma	2.89e-05	7.14e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—BRAF—melanoma	2.87e-05	7.1e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PLCB4—melanoma	2.87e-05	7.1e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGF1—melanoma	2.85e-05	7.04e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CSF2—melanoma	2.85e-05	7.04e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL8—melanoma	2.8e-05	6.92e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—E2F1—melanoma	2.78e-05	6.89e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGF2—melanoma	2.78e-05	6.88e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—KRAS—melanoma	2.77e-05	6.86e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—KRAS—melanoma	2.76e-05	6.83e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PDGFRA—melanoma	2.76e-05	6.82e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDKN1B—melanoma	2.73e-05	6.76e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ITGB3—melanoma	2.73e-05	6.75e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PRKCA—melanoma	2.73e-05	6.75e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MAP2K1—melanoma	2.7e-05	6.68e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIP4K2A—melanoma	2.7e-05	6.67e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC6A11—melanoma	2.7e-05	6.67e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CD—melanoma	2.68e-05	6.64e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CASP3—melanoma	2.68e-05	6.63e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SPP1—melanoma	2.68e-05	6.62e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2—melanoma	2.67e-05	6.62e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAP2K2—melanoma	2.67e-05	6.6e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3CA—melanoma	2.65e-05	6.56e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BCL2—melanoma	2.64e-05	6.54e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTAP—melanoma	2.62e-05	6.49e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNG—melanoma	2.62e-05	6.48e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCND1—melanoma	2.61e-05	6.45e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MDM2—melanoma	2.6e-05	6.44e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CTNNB1—melanoma	2.58e-05	6.39e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGF2—melanoma	2.57e-05	6.36e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ERBB2—melanoma	2.57e-05	6.35e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3CA—melanoma	2.55e-05	6.3e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TERT—melanoma	2.54e-05	6.28e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3CA—melanoma	2.53e-05	6.27e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CB—melanoma	2.53e-05	6.27e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP9—melanoma	2.53e-05	6.26e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RAC1—melanoma	2.53e-05	6.26e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD4—melanoma	2.53e-05	6.26e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDKN1A—melanoma	2.52e-05	6.24e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTEN—melanoma	2.52e-05	6.23e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NFKB1—melanoma	2.5e-05	6.2e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HRAS—melanoma	2.45e-05	6.07e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HIF1A—melanoma	2.43e-05	6e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MDM2—melanoma	2.4e-05	5.95e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDKN1B—melanoma	2.38e-05	5.88e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ERBB2—melanoma	2.37e-05	5.86e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HRAS—melanoma	2.35e-05	5.83e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—melanoma	2.35e-05	5.81e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HRAS—melanoma	2.34e-05	5.8e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CB—melanoma	2.34e-05	5.79e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PHGDH—melanoma	2.34e-05	5.79e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LUM—melanoma	2.34e-05	5.79e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD4—melanoma	2.33e-05	5.78e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2—melanoma	2.33e-05	5.76e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KDR—melanoma	2.32e-05	5.74e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—melanoma	2.32e-05	5.73e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HPSE—melanoma	2.29e-05	5.67e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—melanoma	2.27e-05	5.62e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CUBN—melanoma	2.25e-05	5.57e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STAT3—melanoma	2.25e-05	5.57e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CTNNB1—melanoma	2.25e-05	5.56e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NRAS—melanoma	2.24e-05	5.55e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—melanoma	2.24e-05	5.55e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FN1—melanoma	2.23e-05	5.53e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN1B—melanoma	2.19e-05	5.43e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDKN1A—melanoma	2.19e-05	5.43e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTEN—melanoma	2.19e-05	5.42e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOTCH1—melanoma	2.19e-05	5.41e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NFKB1—melanoma	2.18e-05	5.39e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SDHD—melanoma	2.17e-05	5.38e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CSPG4—melanoma	2.17e-05	5.38e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—BSG—melanoma	2.17e-05	5.38e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT1—melanoma	2.17e-05	5.36e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAPK3—melanoma	2.15e-05	5.32e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CD80—melanoma	2.14e-05	5.3e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KIT—melanoma	2.14e-05	5.29e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CG—melanoma	2.14e-05	5.29e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APC—melanoma	2.14e-05	5.29e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGF—melanoma	2.11e-05	5.23e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPAM—melanoma	2.11e-05	5.21e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MYC—melanoma	2.09e-05	5.17e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT1—melanoma	2.08e-05	5.15e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CTNNB1—melanoma	2.07e-05	5.13e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT1—melanoma	2.07e-05	5.12e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAPK1—melanoma	2.05e-05	5.06e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGFR—melanoma	2.04e-05	5.06e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN1A—melanoma	2.03e-05	5.01e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTEN—melanoma	2.02e-05	5e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—BRAF—melanoma	2.01e-05	4.97e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—STAT3—melanoma	1.96e-05	4.84e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF1—melanoma	1.96e-05	4.84e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NRAS—melanoma	1.95e-05	4.83e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KRAS—melanoma	1.93e-05	4.78e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAP2K1—melanoma	1.89e-05	4.68e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CD—melanoma	1.88e-05	4.65e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAPK3—melanoma	1.87e-05	4.63e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—STAT3—melanoma	1.81e-05	4.47e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NRAS—melanoma	1.8e-05	4.46e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGF2—melanoma	1.8e-05	4.45e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PLA2G6—melanoma	1.79e-05	4.43e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAPK1—melanoma	1.78e-05	4.4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGFR—melanoma	1.78e-05	4.4e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CA—melanoma	1.77e-05	4.39e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MAPK3—melanoma	1.73e-05	4.27e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—melanoma	1.72e-05	4.25e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MDM2—melanoma	1.68e-05	4.16e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KRAS—melanoma	1.68e-05	4.16e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MYC—melanoma	1.68e-05	4.16e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ERBB2—melanoma	1.66e-05	4.11e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MAPK1—melanoma	1.64e-05	4.07e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGFR—melanoma	1.64e-05	4.06e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HRAS—melanoma	1.64e-05	4.06e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CB—melanoma	1.64e-05	4.05e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—VCAN—melanoma	1.61e-05	3.98e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL8—melanoma	1.57e-05	3.89e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—melanoma	1.57e-05	3.89e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KRAS—melanoma	1.55e-05	3.84e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CA—melanoma	1.54e-05	3.82e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN1B—melanoma	1.54e-05	3.8e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CASP3—melanoma	1.51e-05	3.73e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2—melanoma	1.5e-05	3.72e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCND1—melanoma	1.47e-05	3.63e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CTNNB1—melanoma	1.45e-05	3.59e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT1—melanoma	1.45e-05	3.59e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HRAS—melanoma	1.43e-05	3.53e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CA—melanoma	1.43e-05	3.53e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP9—melanoma	1.42e-05	3.52e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN1A—melanoma	1.42e-05	3.51e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTEN—melanoma	1.41e-05	3.5e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NFKB1—melanoma	1.41e-05	3.48e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—melanoma	1.37e-05	3.38e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP17A1—melanoma	1.36e-05	3.36e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HRAS—melanoma	1.32e-05	3.26e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GNA11—melanoma	1.28e-05	3.17e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—melanoma	1.28e-05	3.16e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STAT3—melanoma	1.27e-05	3.13e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NRAS—melanoma	1.26e-05	3.12e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—melanoma	1.26e-05	3.12e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT1—melanoma	1.26e-05	3.12e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—FASN—melanoma	1.25e-05	3.1e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC5A5—melanoma	1.23e-05	3.05e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAPK3—melanoma	1.21e-05	2.99e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CD44—melanoma	1.19e-05	2.95e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GNAQ—melanoma	1.19e-05	2.95e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MYC—melanoma	1.18e-05	2.91e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT1—melanoma	1.16e-05	2.88e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAPK1—melanoma	1.15e-05	2.85e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGFR—melanoma	1.15e-05	2.85e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP1B1—melanoma	1.14e-05	2.83e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KRAS—melanoma	1.09e-05	2.69e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CA—melanoma	9.98e-06	2.47e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—melanoma	9.66e-06	2.39e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCB1—melanoma	9.4e-06	2.33e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HRAS—melanoma	9.23e-06	2.29e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—melanoma	8.84e-06	2.19e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PRKCA—melanoma	8.65e-06	2.14e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ERCC2—melanoma	8.58e-06	2.12e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT1—melanoma	8.15e-06	2.02e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CG—melanoma	6.78e-06	1.68e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARG—melanoma	6.54e-06	1.62e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CD—melanoma	5.96e-06	1.47e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALB—melanoma	5.88e-06	1.46e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CB—melanoma	5.19e-06	1.29e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—melanoma	5.15e-06	1.27e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTEN—melanoma	4.49e-06	1.11e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CA—melanoma	3.17e-06	7.84e-06	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKT1—melanoma	2.59e-06	6.4e-06	CbGpPWpGaD
